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Abstract
Background: Cancer patients routinely develop symptoms consistent with profound circadian disruption, which
causes circadian disruption diminished quality of life. This study was initiated to determine the relationship
between the severity of potentially remediable cancer-associated circadian disruption and quality of life among
patients with advanced lung cancer.
Methods: We concurrently investigated the relationship between the circadian rhythms of 84 advanced lung
cancer patients and their quality of life outcomes as measured by the EORTC QLQ C30 and Ferrans and Powers
QLI. The robustness and stability of activity/sleep circadian daily rhythms were measured by actigraphy. Fifty three
of the patients in the study were starting their definitive therapy following diagnosis and thirty one patients were
beginning second-line therapy. Among the patients who failed prior therapy, the median time between
completing definitive therapy and baseline actigraphy was 4.3 months, (interquartile range 2.1 to 9.8 months).
Results: We found that circadian disruption is universal and severe among these patients compared to non-cancer-
bearing individuals. We found that each of these patient’s EORTC QLQ C30 domain scores revealed a compromised
capacity to perform the routine activities of daily life. The severity of several, but not all, EORTC QLQ C30 symptom
items correlate strongly with the degree of individual circadian disruption. In addition, the scores of all four Ferrans/
Powers QLI domains correlate strongly with the degree of circadian disruption. Although Ferrans/Powers QLI domain
scores show that cancer and its treatment spared these patients’ emotional and psychological health, the QLI Health/
Function domain score revealed high levels of patients’ dissatisfaction with their health which is much worse when
circadian disruption is severe. Circadian disruption selectively affects specific Quality of Life domains, such as the
Ferrans/Powers Health/Function domain, and not others, such as EORTC QLQ C30 Physical Domain.
Conclusions: These data suggest the testable possibility that behavioral, hormonal and/or light-based strategies to
improve circadian organization may help patients suffering from advanced lung cancer to feel and function better.
Background
Oscillators with a circadian (about 24-hr) period syn-
chronize and co-ordinate the behavior of biological sys-
tems at all levels of biological complexity, to specific
phases of the geophysical day [1-7]. Desynchronizing an
individual’s circadian system with the phase of the
geophysical day adversely affects health, mental and
physical, as well as psychological function and health-
related quality of life [8-10]. Cancer patients experience
a deterioration in the robustness (amplitude) and day-
to-day phase stability of their rest/activity rhythms that
faithfully and quantitatively reflect cancer stage, patient
performance status, and prior treatment status [10-15].
Consequently, cancer patients develop specific symptom
clusters pathognomonic of a disrupted circadian organi-
zation, including poor nighttime sleep quality, depressed
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lethargy; and anorexia, early satiety, and diminished
taste sensation [15-21]. The occurrence of these sickness
behaviors among individuals suffering circadian disrup-
tion strongly suggests that a disrupted circadian organi-
zation adversely affects a patient’s quality of life. Lung
cancer is the most prevalent lethal cancer in the devel-
oped and developing world. However, there have been
few investigations on the relationship between lung can-
cer patients’ circadian organization and their quality of
life [10,15].
Linking changes in a patients’ circadian organization
to their quality of life is a complicated process. Quality
of life is measured using a diverse assortment of out-
comes that range across physical, psychological, social,
and spiritual domains. Furthermore, for each assessed
q u a l i t yo fl i f ec a t e g o r yt h e r ea r eav a r i e t yo fd i f f e r e n t
instruments. Physical domain assessment may measure
symptoms, or the patient’s ability to meet the challenges
of daily life, or adjustment to illness [22]. Quality of life
is, thereby, a multidimensional concept, within which
each specific category has a range of unique attributes.
Wilson and Cleary [23] have developed a quality of life
model that expresses the relevant logical connections
among several quality of life measurements along a
sequential pathway. This pathway establishes that phy-
siological disturbances produce symptoms in patients
that change their functional health, which in turn affects
the patients’ perceptions of their general health, which
in turn contributes directly to their perceptions of their
overall quality of life.
We measured circadian organization non-invasively
using wrist actigraphs [24-28]. We also implemented the
EORTC QLQ-C30 to measure the existence and inten-
sity of the patient’s symptoms (symptom status) as well
as the patient’s perception of his or her functional
health [29,30]. We also utilized the Ferrans/Powers
Quality of Life Index (QLI) to measure the patient’s
level of satisfaction with how well their current life
achieves an acceptable level of well being [22,31].
Methods
Patients
Patients participating in this investigation were recruited
for a clinical trial that was conducted concurrently at
Cancer Treatment Centers of America
® (CTCA) at
Midwestern Regional Medical Center (MRMC) in Zion,
Illinois and the WJB Dorn Veterans Medical Center
(VAMC) in Columbia, South Carolina from June 2002
to April 2006. Patients between the ages of 18 and 80
who had a pathologically confirmed diagnosis of stage
III or IV non-small cell lung cancer (NSCLC) and an
Eastern Cooperative Oncology Group (ECOG) perfor-
mance status of 0, 1, or 2 were eligible. Untreated
patients and patients who had failed one prior che-
motherapy treatment regimen were eligible. All patients
signed an Informed Consent indicating that they were
aware of the investigational nature of the study. The
Institutional Review Boards at MRMC and VAMC
approved the study. This current report is based only
upon baseline data obtained at initial enrollment.
Control Subjects
Our control database for actigraphic parameters is com-
prised of 3- to 7-day actigraphy measurements from 35
adults, aged 20 to 50 years, each having no known dis-
ease (Action-W2 database, AMI, NY, USA). EORTC
QLQ-C30 Reference Population data is from a survey of
1,313 newly diagnosed lung cancer patients with stage
III and IV disease,
32 while the EORTC QLQ-C30 Gen-
eral Population data is from a survey of 1,965 randomly
selected subjects in Norway aged eighteen to ninety-
three years [33]. Ferrans/Powers QLI Health/Function-
ing General Population data is taken from 339 subjects,
drawn randomly from a telephone directory represent-
ing urban, suburban, and rural areas in the Midwestern
United States, who completed the QLI questionnaire (C.
Ferrans, Feb 2009).
Protocol Summary
All patients agreed to complete their baseline quality of
life questionnaires before undergoing their initial che-
motherapy treatment cycle for this trial. At MRMC,
actigraphy was performed in the inpatient setting imme-
diately before (24-48 hours) and during their first che-
motherapy cycle. VAMC actigraphy was obtained in the
patients’ domestic setting, prior to their initial cycle of
chemotherapy.
EORTC QLQ-C30 and LC-13
The thirty question European Organization for Research
and Treatment of Cancer Quality of Life Questionnaire
(EORTC QLQ-C30) and the thirteen question Lung
Cancer Questionnaire (LC-13), were developed by clini-
cal trialists to measure lung cancer patients’ ability to
fulfill the routine activities of daily life.
29 On the
EORTC QLQ-C30, five function domains are used to
measure physical, role, emotional, social, and cognitive
functions. In addition, the EORTC QLQ-C30 measures
the following symptom items; fatigue, nausea/vomiting,
loss of appetite, pain, dyspnoea, insomnia, and financial.
On the LC-13, has both multi-item and single-item
measures of lung cancer associated symptoms. Six of
the questions measure the four lung cancer associated
symptoms items: coughing, haemoptysis, dyspnoea and
pain. The other questions measure the side-effects from
conventional chemo- and radiotherapy: hair loss, neuro-
pathy, sore mouth and dysphagia. The possible scores
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functional domains indicate better Quality of Life and
lower scores in the symptom items indicate better Qual-
ity of Life.
Ferrans and Powers Quality of Life Index (QLI) Cancer
Version III
The Ferrans and Powers Quality of Life Index (QLI) dif-
fers from the EORTC QLQ-C30 in that it elicits infor-
mation quantifying each patient’s satisfaction or
dissatisfaction with various aspects of life and thus
assesses the individual’s feelings of emotional well-being
and capacity to enjoy life. Consequently, this instrument
evaluates how cancer has affected, both positively and
negatively, the patient’s well being in terms of their own
personal values [22]. The QLI Cancer Version III con-
sists of two parts. Part one requires the patient to
describe satisfaction levels with 33 aspects of life. Part
two requires the patient to rate the importance of the
same 33 aspects of his or her life. The QLI produces an
overall quality of life score and subscale scores on four
specific domains: health and functioning, social and eco-
nomic, psychological and spiritual, and family. The
scores range from 0 to 30, with higher scores indicating
greater satisfaction with life. Thus, the EORTC-QLQ
C30 and the QLI provide distinct, unique, and comple-
mentary insights into different aspects of each patient’s
quality of life [34].
Actigraphy Measurements of Rest-Activity Cycles
A watch-like wrist actigraph, worn on the non-dominant
wrist, was used to record a patient’s movement patterns
continuously over a four to seven day span (Ambulatory
Monitoring, Inc, AMI, Ardsley, NY USA). Internal
motion sensors (accelerometers) capture patient move-
ment data, measured as the number of accelerations per
minute. These data are transferred to a computer for
analysis to produce a report containing parameters of
activity during each sleep and wake period, detailing
their extent, timing, duration and other characteristics
[35]. Actigraphy data were recorded in the hospital set-
ting at MRMC in the four to seven days immediately
prior to and during the first treatment, while these data
were obtained in the patient’s home for VAMC patients
during the week prior to the first treatment.
Determination of Presence and severity of Chronic
Obstructive Pulmonary Disease (COPD)
C h r o n i cO b s t r u c t i v eP u l m o n a r yD i s e a s e( C O P D )i s
common among lung cancer patients and, thereby, a
potential confounding variable for this investigation of
quality of life outcomes and circadian time structure. All
VA patients were assessed clinically and with pulmonary
functions for the presence of COPD. Its severity was
graded according to the Spirometric Classification of
COPD severity, by reference to percent of predicted
forced expiratory volume in one second (FEV1). Thirty
to fifty percent of predicted FEV1 is considered severe;
moderate is 50 to 80%; and mild COPD is greater than
80% of predicted FEV1. No such data were available for
inpatients.
Statistical Analysis
Descriptive statistics such as mean and standard error
were computed for continuous variables and actigraphy
endpoints to describe the average and variability of
values across the population. Frequency and percentages
were computed for qualitative factors such as sex and
quality of life outcomes. Both parametric (Analysis of
Variance) and non-parametric analyses were used to
determine time of day differences among factor levels
(SAS v 9.1, Cary, NC) and their shapes across (circa-
dian) time of day. For four to seven days, an actigraphy
watch recorded the number of accelerations per minute.
These data were translated into polysomnographically-
validated sleep/activity parameters through the Act Mil-
lenium and Action W2 software (Ambulatory Monitor-
ing, Inc). Cosinor analysis was done on these sleep/
activity patterns in order to assess the circadian charac-
teristics of sleep and activity among these lung cancer
patients. Cosinor analysis provides three standard para-
meters: mesor - the average activity over the 24-hr per-
iod, amplitude - peak to nadir difference and acrophase
- the time of daily peak activity. We also computed
measures of circadian rhythm robustness and day-to-day
stability (circadian quotient = amplitude/mesor), peak
activity (mesor + amplitude) and 24 hour autocorrela-
tion for each patient. We further measured circadian
indices of the daily timing of sleep and activity, such as
the ratio of amount of activity during the day to night-
time activity, night/day sleep balance that is the amount
of nighttime sleep relative to daytime sleep. Inpatient
and outpatient differences were tested using t-test for
quantitative characteristics while chi-square was used
for categorical factors. The relationships between quality
of life domain values and actigraphy measurements were
measured using the Spearman rank correlation test.
Results
Patient Characteristics
84 patients were enrolled and consented at two sites. One
site studied patients only in the outpatient home environ-
ment while the second site studied them only as inpati-
ents. There were differences in demographic and clinical
status in participants by site. All 42 outpatients were
males while 19 of 42 inpatients were female. Outpatients
were older on average with a mean age of 66 compared
to the inpatients’ mean age of 57 years (Table 1). More
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(47.6%).
50% and 26% of inpatients and outpatients, respec-
tively, were experiencing recurrence of disease after first
line systemic treatment failure. The median time
between terminating first line therapy and the adminis-
t r a t i o no fa c t i g r a p h yi nt h et e no u t p a t i e n t sw a s5 1 . 6
months (range 7.9 to 78 months), but for inpatients it
was 3.5 months (0.8 to 33.5 months).
Assessment of Patient Evaluability
Although all patients agreed to wear the actigraphs,
twelve actigraphs were worn for less than 48 hours and/
or had frequent missing observations due to instrument
malfunction. Four patients failed to respond fully to the
questionnaires, so we have full actigraphy and full ques-
tionnaire data for 68 of these 84 patients.
Quality of Life
Both inpatients and outpatients reported lower scores
for all EORTC-QLQ-C30 functional domains when
compared to population-based controls (Table 2). The
differences in domain scores between these lung cancer
patients and population-based controls were large, ran-
ging from 16 to nearly 30 points. Both inpatients and
outpatients reported scores that were 20 to 30 points
higher (worse) than the population based controls in the
symptom items of fatigue, loss of appetite, insomnia,
and pain. Our advanced lung cancer patients, as
expected, also scored 10 to 20 points higher (worse) on
these symptom items than the EORTC reference popu-
lation of newly diagnosed lung cancer patients with
stage III and IV disease. Despite various demographic
and clinical differences between inpatients and outpati-
ents, only two of 20 symptom categories, fatigue (p =
Table 1 Distribution of patient demographic and clinical variables by site
Demographic/Clinical
a Inpatients (n = 42) Outpatients (n = 42) Site Difference (c
2,p )
b
Age in years (Mean; Range) 57 (40-78)* 66 (47-94) 4.0, < 0.01
c
Sex (M:F) 23:19* 42:0 24.6, < 0.01
Cancer Stage (IIIA&B: IV) 10:32 9:33 2.1, 0.36
Prior Therapy (Yes:No) 21:20
d* 10:32 6.7, 0.01
WHO ECOG (0:1:2) 17:18:07 13:24:04
d 2.2, 0.33
COPD (No:Mild:Mod:Severe)
c 14:7:13:8
aValues are numbers of patients except for Age.
bBased on chi-square test.
cBased on t-test.
dOne patient at MRMC lacked documentation of prior therapy, while
another patient at VAMC lacked documentation on ECOG scale. *Significant difference at p < 0.05 compared to outpatients.
Table 2 Distribution of EORTC QLQ-C30 domain and symptom item scales by site
Domain Study Population (mean ± se) General Population
c (mean) Reference Population
d [mean (SD)]
All Patients Inpatients Outpatients
Global Score
a 50.78 ± 3.15 49.80 ± 4.84 51.96 ± 3.86 - 54.7 (23.8)
Functional Scales
a
Physical 64.53 ± 3.15 73.33 ± 4.22* 53.92 ± 4.12* 89.9 65.9 (25.6)
Role 54.44 ± 4.28 60.57 ± 6.01 47.06 ± 5.91 83.3 55.5 (34.5)
Emotional 59.52 ± 3.31 59.96 ± 4.24 58.99 ± 5.29 82.8 67.3 (24.1)
Cognitive 70.22 ± 3.18 76.02 ± 4.15 63.24 ± 4.71 86.5 81.6 (22.7)
Social 55.33 ± 3.77 51.22 ± 5.35 60.29 ± 5.22 85.8 69.8 (30.3)
Symptom Scales
b
Fatigue 52.00 ± 3.55 45.26 ± 4.63* 60.29 ± 5.22* 28.8 44.2 (27.5)
Nausea 15.78 ± 2.53 14.63 ± 3.30 17.16 ± 3.95 4 10.8 (19.1)
Pain 53.33 ± 4.38 48.37 ± 6.10 59.31 ± 6.22 20.5 34.7 (32.3)
Single Items
b
Dyspnoea 46.22 ± 3.79 36.58 ± 4.33* 57.84 ± 6.02* 14.3 40.7 (32.2)
Insomnia 44.00 ± 3.91 39.84 ± 4.97 49.02 ± 6.17 20.4 34.8 (33.4)
Appetite Loss 39.11 ± 3.97 33.33 ± 4.94 46.08 ± 6.30 7.5 31.1 (34.6)
Constipation 29.33 ± 3.90 26.83 ± 4.83 32.35 ± 6.37 10.4 22.2 (31.7)
Diarrhea 7.11 ± 2.03 5.69 ± 2.83 8.82 ± 2.92 9.4 7.3 (18.1)
aHigher scores indicate better daily function, thus better quality of life.
bLower scores indicate fewer symptoms, thus better quality of life.
cEORTC general
population of 1,965 randomly selected subjects ages 18 to 93 years (Hjermstad, et. al. J Clin Oncol 1998).,
dEORTC reference population of 1,313 lung cancer
patients with stage III and IV disease (Scott, et. al. EORTC Reference Manual 2008). *Inpatients versus Outpatients are significantly different, p < 0.05.
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statistical significance between our two patient groups,
indicating the profound leveling effect of advanced non-
small cell lung cancer vis a vis their most common and
devastating symptoms.
Our patients’ mean score of 16.23 in the Ferrans/
Powers QLI health/functioning domain is nearly eight
points lower (worse) than the population-based mean
score. This is some two standard deviations below
mean scores from a general population survey. Patients
were very dissatisfied with their health. Interestingly,
however, the other three QLI domains (social/eco-
nomic, psychological/spiritu a lw e l lb e i n g ,a n df a m i l y )
did not differ at all from the population-based scores
(Table 3).
Actigraphy
Actigraphic parameters of lung cancer patients were
found to be grossly abnormal when compared to the
healthy control population. Healthy individuals show a
more robust 24-hour activity rhythm while lung cancer
patients show a flatter curve (Figure 1). Cancer patients
were 30% less active and napped at least three times
longer than the controls during the putative wake/activ-
ity period (Table 4). During the nightly sleep span, lung
cancer patients had significantly more and longer wak-
ing episodes than controls (Table 4). No gender differ-
ences were found.
Actigraphy characterizing the putative daily wake span
and the overall circadian organization differed by site
(Table 4, Figure 1). Outpatients were more active during
the day and consolidated activity and sleep better com-
pared to hospitalized inpatients. The sleep phase actigra-
phy parameters at both sites, however, were
indistinguishable. These prominent site specific differ-
ences in actigraphy collection protocol required that all
such data be analyzed by site. The most obvious ubiqui-
tous and severe differences across the groups of normal
controls and lung cancer patients include uniformly
poor sleep among all lung cancer patients and decreas-
ing daytime activity which is most severe, as might be
expected, among hospitalized patients.
Correlation of Quality of Life and Actigraphy among
Inpatients
Among inpatients we only found several statistically sig-
nificant associations with actigraphy parameters. We
found that the QLI Health/Functioning domain scores
correlate with the 24-hour activity autocorrelation,
which measures day to day stability of the peak and
trough timings of the daily activity/sleep pattern (r =
0.34, p = 0.05). Inpatients with the most stable circadian
time structures of the daily activity pattern express the
highest level of satisfaction with their health. Those who
are most disrupted have much worse satisfaction with
their health. Two EORTC symptom items correlated
strongly with activity circadian rhythm parameters;
insomnia severity correlates negatively with 24-hour
autocorrelation, the day-to-day reproducibility of peak
and trough activity (r = -0.48, p = 0.003), and loss of
appetite correlates with decreased peak daily activity (r
= -0.41, p = 0.005) and Circadian Quotient, a measure
of the strength of the circadian rhythm compared to
noise or other high frequency rhythms (r = 0.4, p =
0.015). Circadian activity/sleep rhythm disruption is
reflected in or caused by nocturnal insomnia and those
patients with most decreased daily activity (ie. greatest
daytime fatigue) have the poorest appetite, even in the
hospital setting.
Relationships between QLI and Actigraphy among
Outpatients
Among ambulatory outpatients with advanced lung can-
cer in their own homes, higher levels of daytime activity,
as measured by the parameter “peak activity,” is signifi-
cantly associated with each of the five Power and Ferrans
QLI domains: health/functioning(r = 0.51, p < 0.01),
social/economic (r = 0.38, p = 0.048), psychological/spiri-
tual (r = 0.45, p = 0.02), family (r = 0.45, p = 0.02), and
overall QLI (r = 0.57, p < 0.01), see Figure 2 and Table 5.
Robustness (largest peak to trough difference in daily
activity or amplitude) of objectively measured daytime
activity is reflective of all measured aspects of quality of
life in the face of advanced lung cancer. The health/func-
tioning domain also demonstrates a statistically
Table 3 Distribution of Powers and Ferrans QLI domain scores by site
Domain Study Population (mean ± se) General Population
b [mean (SD)]
All Patients Inpatients Outpatients
Health & Functioning
a 16.23 ± 0.72* 15.13 ± 1.14 17.55 ± 0.0.73 23.19 (4.47)*
Social/Economic
a 21.15 ± 0.46 21.21 ± 0.58 21.08 ± 0.74 21.83 (4.11)
Psychological/Spiritual
a 21.57 ± 0.71 21.04 ± 0.88 22.21 ± 1.16 22.95 (5.21)
Family
a 23.22 ± 0.60 24.50 ± 0.75 21.68 ± 0.89 25.60 (4.49)
Overall Quality of Life
a 19.61 ± 0.48 19.28 ± 0.69 20.02 ± 0.66 23.00 (4.04)
aHigher scores indicate greater satisfaction with life.
bPowers and Ferrans QLI General Population is taken from a database of 339 randomly selected subjects
ages 18 and above (C. Ferrans, Feb 2009). *Study Population scores are markedly lower than General Population scores.
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Page 5 of 13Figure 1 Comparison of the circadian activity rhythm of healthy controls and lung cancer patients. Healthy controls (A)s h o wam o r e
robust circadian activity rhythm compared to lung cancer inpatients and outpatients combined (B). Outpatients (C) have better circadian
organization of sleep/activity compared to the hospitalized group (D). Concurrent plot of all groups (E) shows that peak daytime activity is
compromised in all lung cancer patients and especially among hospitalized ones. Nightly sleep is, however, markedly and identically disturbed
among lung cancer patients regardless of where it is measured.
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tion, or day-to-day circadian stability of peak and trough
activity timings (r = 0.45, p = 0.02). Each Ferrans-Powers
QLI domain exhibits a statistically significant relationship
with the actigraphy parameter night-day sleep balance
and quality of life scores in health/functioning (r = 0.39,
p = 0.04), social/economic (r = 0.40, p < 0.04), psycholo-
gical/spiritual (r = 0.45, p = 0.02), and family (r = 0.33, p
= 0.10). The more robust the day/night difference
between nocturnal and daytime activity levels, the better
the patients score by each and every QLI measure.
Relationships between EORTC QLC 30 and Actigraphy-
measured Circadian Function
Statistically significant correlations between EORTC
QLQ C30 domains among outpatients were found. Glo-
bal health exhibits a statistically significant positive asso-
ciation with circadian phase stability as reflected by the
24-hour autocorrelation (r = 0.53, p < 0.01), (see figure
2). The actigraphy parameter, night-day balance of time
spent asleep and awake, shows a statistically significant
association with the EORTC QLQ C30 domains role (r
= 0.56, p < 0.01) and cognitive function (r = 0.45, p =
0.02).
Circadian Organization and EORTC Symptom Items
Outpatient fatigue levels are associated with diminished
robustness of the circadian quotient (r = -0.40, p =
0.04), rhythm quotient (r = -0.41, p = 0.03) and night-
day balance of time spent asleep (r = -0.52, p < -.01).
The more quantitatively robust the day-night activity/
sleep measurement differences, the less fatigue these
patients experience during each day. Rhythm quotient is
also inversely associated with pain (r = -0.39, p = 0.04).
The greater the pain, the less robust were day-night
activity differences, objectively verifying that pain inter-
feres with both sleep at night and activity during each
day. Loss of appetite is likewise associated negatively
with the actigraphy parameters night-day sleep balance
(r = -0.47, p < 0.01). The more disordered the circadian
organization, the more profound the cancer-associated
loss of appetite.
Unlike the analysis for quality of life outcomes, there
were no statistically significant associations found
between actigraphy data and chronic COPD severity in
this patient population with symptomatic advanced lung
cancer.
Relationships of Quality of Life Scores to one another and
to Circadian Organization
Figure 3 shows the relationships among two measures of
quality of life and circadian organization parameters. A
robust circadian rhythm in activity/rest is associated
with greater patient satisfaction with health/functioning,
less fatigue, and better overall quality of life. These rela-
tionships, though present among all patients, are espe-
cially clear among outpatients where hospitalization
does not mask usual circadian time structure.
Discussion
Circadian organization optimizes organismal function at
all levels of biological organization [4,39,40]. A faltering
Table 4 Actigraphic sleep-activity characteristics of non-small cell lung cancer patients compared to normal
individuals during the putative wakefulness and during the putative sleepfulness
Parameters All patients Inpatients Outpatients Healthy Controls
N6 8 3 5 3 3 3 5
Daytime Activity
Mean Activity (accel/min) 126.9 ± 4.9 111.7 ± 7.1 143.0 ± 5.6 182.6 ± 25
Wake Minutes 797.5 ± 26 714.2 ± 36 885.8 ± 31 947.1 ± 11
Sleep Minutes 208.8 ± 18 241.3 ± 25 174.4 ± 24 46.5 ± 6.9
% Sleep 20.9 ± 1.8 25.8 ± 2.8 15.6 ± 1.9 4.7 ± 0.7
Duration of Longest Sleep (min) 43.0 ± 2.8 45.4 ± 4.0 40.5 ± 3.9 23.6 ± 0.6
Nighttime
Wake Minutes 95.0 ± 8.8 97.5 ± 12.2 92.3 ± 12.9 31.1 ± 3.6
Sleep Minutes 284.0 ± 18.3 300.5 ± 24.8 266.4 ± 27.2 417.89.4
% Sleep 72.5 ± 2.0 73.3 ± 2.6 71.6 ± 3.08 93.0 ± 0.8
Sleep Efficiency (%) 79.8 ± 1.7 80.8 ± 2.4 78.7 ± 2.5 95.9 ± 0.7
Duration of Longest Sleep 91.7 ± 7.4 100.3 ± 11.8 82.5 ± 8.6 225.6 ± 17
Sleep Latency (min) 20.8 ± 2.5 18.1 ± 2.9 23.7 ± 4.0 12.1 ± 6.9
*Inpatient vs. Outpatient difference is significant for all parameters (t-test, p < 0.05).
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from the fairly minor, such as jet lag, to life limiting dis-
orders like depression, metabolic syndrome, cardiovas-
cular or gastrointestinal disease, or cancer [41]. A
breakdown of circadian organization can result in death
in lab animals and may contribute to death in humans
[39,42-45].
Cancer bearing degrades circadian organization, which
diminishes an individual’s health and capacity to meet
the demands of daily life [10,46,47]. Apparently, a
patient’s health-related quality of life is adversely
affected when the level of disruption of an individual’s
circadian organization exceeds a threshold [48].
Our actigraphy data show that non small cell lung
cancer patients’ circadian activity/rest rhythms are
markedly and characteristically distorted when com-
pared to apparently healthy individuals. Our advanced
lung cancer patients’ daily activity levels are much lower
Figure 2 Relationship between quality of life and circadian organization among inpatients and outpatients. Lung cancer patients who
are most quiet in the nighttime and active during the day (highest circadian Rhythm Quotient) are the least fatigued, both in hospitalized and
at home settings (A). The more stable the day-to-day pattern of daily activity and nighttime sleep (24-hour Autocorrelation), the better the
overall ability to fulfill daily functions among outpatients (B), and the greater the patient’s satisfaction with his/her health among inpatients and
outpatients (C). The greater the peak activity, the greater the patient’s overall satisfaction with life among outpatients (D, E).
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Page 8 of 13than population-based control data. Our patients took
many prolonged daytime naps, while suffering many epi-
sodes of prolonged awakening for prolonged spans dur-
ing each night. Similar findings have been reported for
patients early stage breast cancer and metastatic color-
ectal cancer [52,53]. These patients also reported quality
of life outcomes that were significantly lower than popu-
lation based controls. Our patients’ responses to the
EORTC instrument reveal they were experiencing multi-
ple symptoms and their capacity to meet the challenges
of routine life was compromised. Our patients, like
others with advanced cancer, were very dissatisfied with
their health. Every patient self report for the QLI
health/functioning domain fell within the bottom quar-
tile as compared to the general population scores, indi-
cating a uniformly high level of dissatisfaction with their
physical health. On the other hand, their scores for the
other three QLI domains, social/economic, family, and
psychological/spiritual were indistinguishable from those
of the general population. Our patients were emotionally
and psychologically healthy, despite lethal cancer asso-
ciated ill health. This finding illustrates the resilience of
the human spirit, even in the face of lethal symptomatic
disease and the value of asking questions relevant to the
whole life of the cancer patient.
An interesting finding was the lack of a significant
relationship between a self-reported insomnia among
outpatients and any objectively measured actigraphy
parameter. This finding is surprising considering that
actigraphy data showed that virtually every patient’s
sleep was fragmented and unconsolidated and these
patients’ self reports of their sleep quality, as measured
by a validated sleep questionnaire, was indistinguish-
able from insomniacs [49,50]. This non sequitor
between universal objective signs of very poor sleep
and the perception of insomnia among advanced lung
cancer is interesting. It seems as though, in cancer
patients as in the healthy elderly, the perception of
nocturnal sleeplessness and the reality of it are at
odds. Inpatients did report an association between an
actigraphy parameter and insomnia. We can speculate
that hospital routines inv o l v eas u d d e ni n c r e a s ei n
number of untoward nighttime awakenings that results
in the patients feeling much sleepier than they did in
the prior week. Similar findings have been reported for
patients with metastatic colorectal cancer [52]. Two-
thirds of the patients for whom it was measured suf-
fered from mild, moderate or severe chronic COPD.
There were no statistically significant relationships
between the degree of dyspnea and any parameter of
circadian function. These findings indicate that both
lung cancer and COPD are associated with shortness
of breath but that quality of life decrement is only
associated with cancer symptoms and circadian disrup-
tion and not COPD severity, which is usually relatively
stable and chronic.
Table 5 Statistically Significant (P < 0.05) Correlations between Quality of Life (QoL) Domains and Cosinor Parameters
in Outpatients
QoL Domains Mesor Amplitude Circadian
Quotient
Rhythm
Quotient
24-hr Correlation Night-day Sleep
Balance
EORTC Symptom Items
Fatigue -0.4 -0.41 -0.52
Pain -0.39
Loss of Appetite -0.47
EORTC Functional Domains
Social .34
Role 0.56
Cognitive 0.45
EORTC Global Health item 0.53
Ferrans-Powers QLI Domains
Health/Function 0.44 0.51 0.45 0.39
Social/Economic 0.38 0.39 0.40
Psychological Spiritual .45 0.4 0.45
Family 0.45
Grutsch et al. BMC Cancer 2011, 11:193
http://www.biomedcentral.com/1471-2407/11/193
Page 9 of 13Among outpatients, whose daytime activity levels were
expectedly higher than inpatients, there were many
clinically relevant and statistically significant associations
between most parameters of circadian organization and
cancer associated daytime fatigue that were masked,
weakened or lost among inpatients. We conclude that
all future studies of cancer-related quality of life and cir-
cadian organization should best be done in the patient’s
home, not in the hospital.
All Ferrans-Powers QLI domains, except Family,
which had one statistically significant relationship, had
multiple strong statistically significant relationships with
cosinor and actigraphy parameters of circadian organiza-
tion. Because of this sensitivity and relevance, we believe
that future work should employ the Powers and Ferrans
scales in addition to any other quality of life scales.
Superficially, advanced lung cancer patients appear to
be suffering from non-resolving jet lag; disturbed as well
as diminished non-restorative sleep; and excessive day-
time sleepiness and nighttime wakefulness, daytime fati-
gue, problems with concentration and memory during
the day, and loss of appetite, especially during the sec-
ond half of the waking hours. We found many strong
correlations between all Ferrans-Powers QLI domains of
each individual and most parameters of that individual’s
circadian organization. Apparently a decaying circadian
organization affects a patient’s perception of their health
and emotional/psychological well being before it actually
reduces his/her capacity to fulfill these activities of nor-
mal life. This finding of the possible premonitory value
of circadian status deserves careful additional quality of
life study.
There are several limitations in this study. Our sample
size may not be large enough to accommodate the num-
ber of comparisons made within this study. We una-
voidably lacked, by virtue of the nature of our oncology
Figure 3 The relationships among two measures of quality of life and circadian rhythm stability. The greater the circadian rhythm in
activity/rest, the greater the PF Health and Functioning; the lower the EORTC Fatigue Score (A) and the greater the EORTC Global Health Score
(C) in the group as a whole. These relationships are especially clear among outpatients (B, D). *Significant r, p < 0.05.
†Marginal r, p=0.08.
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Page 10 of 13practices and the VA setting of one of our groups, per-
fect age- and gender-matched comparisons to clearly
evaluate the extent of the affects of sex and age upon
circadian function of our cancer inpatients vs. outpati-
ents. We did, however, obtain relevant actigraphy data
upon 35 healthy controls aged 20 to 30 for comparison.
While not a perfect control, this population provides
reasonable comparison data. The most significant limita-
tion may be that our statistical models are less than
optimally sensitive to linking the degree of disorder in
the patient’s circadian system and advanced lung cancer
symptoms [51].
Despite these very real limitations, our data and those
of others indicate that among cancer patients, circadian
organization is an integrative pathway involved in a vari-
ety of important pathophysiologic processes that promi-
nently and quantitatively affect a variety of quality of life
outcomes. The next step in this program is to determine
whether restoring the robustness of circadian organiza-
tion among advanced cancer patients is possible and
whether doing so will reduce symptom intensity,
improve function and overall satisfaction with their phy-
sical/emotional/psychological health, improve perfor-
mance status and well being, and ultimately determine
whether survival duration can be prolonged by improv-
ing the circadian organization of patients with advanced
cancer.
Conclusions
T h e s ed a t as u g g e s tt h et e s t a b l ep o s s i b i l i t yt h a tb e h a -
vioral, hormonal and/or light-based strategies to
improve circadian organization may help patients suffer-
ing from advanced lung cancer to feel and function
better.
Appendix 1. Circadian Parameters Used
The following parameters described the activity phase
of the daily circadian cycle: mean daily activity, mean
duration of activity during wakefulness, mean duration
of sleep during wakefulness, proportion of wakefulness
spent sleeping, number of sleep episodes during wake-
fulness, and frequency of long naps. During the pre-
sumed sleep phase of the circadian cycle, the following
parameters were evaluated: mean duration of wakeful-
ness, number of sleep interruptions, proportion of
sleep episode spent actually sleeping, and frequency of
long duration of sleep. The number of accelerations
per minute for a continuous 4-7 days was recorded
through the actigraphy watch and was translated into
sleep/activity parameters through the Act Millennium
and Action W2 software (Ambulatory Monitoring,
Inc.).
Rhythmometric analysis (using Chronolab v2) was car-
ried out on these sleep/activity patterns in order to
assess disruption and consolidation of sleep in lung can-
cer patients. Rhythmometric analysis fits a cosine curve
to the circadian activity providing three standard para-
meters: mesor - the average activity over the 24-h per-
iod, amplitude-peak to nadir difference and acrophase -
the time of peak activity. In addition to these para-
meters, peak activity (mesor+amplitude) to measure
activity levels, the circadian quotient (amplitude/mesor)
to characterize the strength of the circadian rhythm,
and the rhythm quotient (A24 h/(A4h +A8h +A12 h)) were
computed. A4h ,A 8h ,a n dA 12 h are the amplitudes of
4-hr, 8-hr and 12-hr cosine fits, respectively. Higher
amplitudes indicate more robust rhythms but people
who move vigorously would have higher amplitude,
thus, the circadian quotient provides normalized values
that would allow comparison between individuals
[54,55].
We also looked at the dichotomy index (I < O), com-
paring amounts of activity when in bed and out of bed,
which is significantly associated with colorectal cancer
patients’ q u a l i t yo fl i f ea n ds u r v i v a l
14.I<Oi st h ep e r -
centage of minutes or epochs during the putative sleep
span with activity score that are less than the median
activity during the putative wakefulness. Thus, high I <
O reflects a marked rest/activity rhythm
15 Further, cir-
cadian rhythms were assessed through spectral density
analysis where 24-hour autocorrelations (r24) were com-
puted. Autocorrelations theoretically can range from 0
to1. If a circadian variation is present, autocorrelations
will increase around 24-hour and a more pronounced
and stable day-to-day circadian rhythm will result in a
higher autocorrelation at 24-hour.
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